Walgreen execs step down following billion-dollar Medicare business projection mistake

Two Walgreen Co. executives have stepped down in the wake of an abrupt $1.1 billion cut in the company’s pharmacy-unit earnings forecast for fiscal year 2016, according to a report from The Wall Street Journal.

Advertisement

In April, then-CFO Wade Miquelon projected $8.5 billion in pharmacy earnings before interest and taxes, partly from contracts the company has entered into to dispense medications under the Medicare Part D prescription drug benefit, according to the report. Pharmacy chains like Walgreen enter into long-term agreements with insurance companies and others that operate Part D plans to dispense various medications for set charges.

However, last month, Mr. Miquelon decreased his forecast by $1.1 billion. He then stepped down earlier this month and has been replaced by Timothy McLevish, a former Kraft executive, according to the report. The company has also announced President of Pharmacy, Health and Wellness Kermit Crawford will retire at the end of the year. Although Mr. Miquelon and Mr. Crawford have said they weren’t forced out, sources “familiar with the decision” told the Journal the two executives were pushed to step down.

As for what caused the forecasting error, the Walgreen finance unit failed to factor an increase in drug manufacturers’ prices for generic medications into April’s projections, according to the report. Walgreen President and CEO Gregory Wasson said in a call with investors earlier this month that the company didn’t “fully anticipate” the rise in generic drug prices. Investors have said company directors told them the finance and pharmacy units didn’t communicate adequately, according to the report.

Walgreen rival CVS Caremark Corp. has said the generic drug price increases weren’t a surprise and haven’t affected its forecasts, according to the report.

More articles on prescription drugs:
Healthcare spending on mental, substance use disorders projected to slow by 2020  
PPACA saved beneficiaries $11.5B in Medicare drug costs, HHS says 
FedEx charged with illegal distribution of prescription drugs, faces $1.6B in penalties 

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.